These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 24233004

  • 1. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H, Shinotoh H, Shimada H, Miyoshi M, Yanai K, Okamura N, Takano H, Takahashi H, Arakawa R, Kodaka F, Ono M, Eguchi Y, Higuchi M, Fukumura T, Suhara T.
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [Abstract] [Full Text] [Related]

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE, Farrar G.
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [Abstract] [Full Text] [Related]

  • 3. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH, Kim BI, Park SY, Ko IO, Lee KC, Kim KM, Kim YK, Lee JY, Bu SH, Kim JH, Chi DY, Ha JH, Lim SM.
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [Abstract] [Full Text] [Related]

  • 4. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.
    Neuroimage; 2010 Aug 15; 52(2):488-96. PubMed ID: 20385246
    [Abstract] [Full Text] [Related]

  • 5. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
    Brown EE, Rashidi-Ranjbar N, Caravaggio F, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Fischer CE, Flint A, Mah L, Herrmann N, Bowie CR, Voineskos AN, Graff-Guerrero A, PACt-MD Study GroupCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada..
    J Neuroimaging; 2019 Nov 15; 29(6):721-729. PubMed ID: 31270885
    [Abstract] [Full Text] [Related]

  • 6. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.
    Neuroimage Clin; 2015 Nov 15; 9():592-8. PubMed ID: 26640770
    [Abstract] [Full Text] [Related]

  • 7. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H.
    Eur J Nucl Med Mol Imaging; 2014 Feb 15; 41(2):290-300. PubMed ID: 24085503
    [Abstract] [Full Text] [Related]

  • 8. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.
    Eur J Nucl Med Mol Imaging; 2012 Dec 15; 39(12):1927-36. PubMed ID: 22926714
    [Abstract] [Full Text] [Related]

  • 9. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R, Tolboom N, Foster-Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, Windhorst AD, Barkhof F, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BN.
    Eur J Nucl Med Mol Imaging; 2012 Jun 15; 39(6):990-1000. PubMed ID: 22441582
    [Abstract] [Full Text] [Related]

  • 10. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.
    J Nucl Med; 2012 Jan 15; 53(1):37-46. PubMed ID: 22213821
    [Abstract] [Full Text] [Related]

  • 11. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K, McCullough A, Franklin EE, Hornbeck R, Gordon B, Sharma V, Cruchaga C, Goate A, Karch C, McDade E, Xiong C, Bateman RJ, Ghetti B, Ringman JM, Chhatwal J, Masters CL, McLean C, Lashley T, Su Y, Koeppe R, Jack C, Klunk WE, Morris JC, Perrin RJ, Cairns NJ, Benzinger TLS.
    Acta Neuropathol; 2021 Oct 15; 142(4):689-706. PubMed ID: 34319442
    [Abstract] [Full Text] [Related]

  • 12. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand.
    Yousefi BH, Manook A, Grimmer T, Arzberger T, von Reutern B, Henriksen G, Drzezga A, Förster S, Schwaiger M, Wester HJ.
    ACS Chem Neurosci; 2015 Mar 18; 6(3):428-37. PubMed ID: 25482310
    [Abstract] [Full Text] [Related]

  • 13. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.
    Neuroimage Clin; 2014 Mar 18; 4():508-16. PubMed ID: 24818077
    [Abstract] [Full Text] [Related]

  • 14. Cortical hypermetabolism in MCI subjects: a compensatory mechanism?
    Ashraf A, Fan Z, Brooks DJ, Edison P.
    Eur J Nucl Med Mol Imaging; 2015 Mar 18; 42(3):447-58. PubMed ID: 25267349
    [Abstract] [Full Text] [Related]

  • 15. 18F-FPYBF-2, a new F-18-labelled amyloid imaging PET tracer: first experience in 61 volunteers and 55 patients with dementia.
    Higashi T, Nishii R, Kagawa S, Kishibe Y, Takahashi M, Okina T, Suzuki N, Hasegawa H, Nagahama Y, Ishizu K, Oishi N, Kimura H, Watanabe H, Ono M, Saji H, Yamauchi H.
    Ann Nucl Med; 2018 Apr 18; 32(3):206-216. PubMed ID: 29388083
    [Abstract] [Full Text] [Related]

  • 16. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.
    Brain; 2008 Jun 18; 131(Pt 6):1630-45. PubMed ID: 18339640
    [Abstract] [Full Text] [Related]

  • 17. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, Kraut MA, Ferrucci L, Mathis CA, Klunk WE, O'Brien RJ, Davatzikos C, Wong DF, Resnick SM.
    Acta Neuropathol; 2012 Dec 18; 124(6):823-31. PubMed ID: 22864813
    [Abstract] [Full Text] [Related]

  • 18. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.
    Neurology; 2007 May 08; 68(19):1603-6. PubMed ID: 17485647
    [Abstract] [Full Text] [Related]

  • 19. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.
    Arch Neurol; 2009 Jan 08; 66(1):60-7. PubMed ID: 19139300
    [Abstract] [Full Text] [Related]

  • 20. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, Tapiola T, Pirttilä T, Rinne J, Jääskeläinen JE, Soininen H, Rinne JO.
    Arch Neurol; 2008 Oct 08; 65(10):1304-9. PubMed ID: 18695050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.